154 related articles for article (PubMed ID: 36348021)
1. ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.
Chaluts D; Dullea JT; Ali M; Vasan V; Devarajan A; Rutland JW; Gill CM; Ellis E; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5165-5172. PubMed ID: 36348021
[TBL] [Abstract][Full Text] [Related]
2. SWI/SNF chromatin remodeling complex alterations in meningioma.
Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
[TBL] [Abstract][Full Text] [Related]
3. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
[TBL] [Abstract][Full Text] [Related]
4. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas.
Mansouri A; Klironomos G; Taslimi S; Kilian A; Gentili F; Khan OH; Aldape K; Zadeh G
J Neurosurg; 2016 Aug; 125(2):431-40. PubMed ID: 26722844
[TBL] [Abstract][Full Text] [Related]
5. Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.
Bujko M; Machnicki MM; Grecka E; Rusetska N; Matyja E; Kober P; Mandat T; Rydzanicz M; Płoski R; Krajewski R; Bonicki W; Stokłosa T; Siedlecki JA
World Neurosurg; 2017 Jan; 97():754.e1-754.e6. PubMed ID: 27756662
[TBL] [Abstract][Full Text] [Related]
6. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.
Leclair NK; Shen E; Wu Q; Wolansky L; Becker K; Li L; Bulsara KR
Acta Neurochir (Wien); 2022 Sep; 164(9):2491-2503. PubMed ID: 35881312
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
9. Is the Simpson Grading System Applicable to Estimate the Risk of Tumor Progression After Microsurgery for Recurrent Intracranial Meningioma?
Schipmann S; Schwake M; Sporns PB; Voß KM; Sicking J; Spille DC; Hess K; Paulus W; Stummer W; Brokinkel B
World Neurosurg; 2018 Nov; 119():e589-e597. PubMed ID: 30081236
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
11. Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas.
Rutland JW; Dullea JT; Gill CM; Chaluts D; Ranti D; Ellis E; Arrighi-Allisan A; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Umphlett M; Shrivastava RK
Neurosurg Focus; 2022 Feb; 52(2):E7. PubMed ID: 35104796
[TBL] [Abstract][Full Text] [Related]
12. The role of radiotherapy following gross-total resection of atypical meningiomas.
Komotar RJ; Iorgulescu JB; Raper DM; Holland EC; Beal K; Bilsky MH; Brennan CW; Tabar V; Sherman JH; Yamada Y; Gutin PH
J Neurosurg; 2012 Oct; 117(4):679-86. PubMed ID: 22920955
[TBL] [Abstract][Full Text] [Related]
13. Benign versus atypical meningiomas: risk factors predicting recurrence.
Nowak A; Dziedzic T; Krych P; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(1):1-10. PubMed ID: 25666766
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of transcription factor
Onoprienko A; Hofstetter G; Muellauer L; Dorittke T; Polterauer S; Grimm C; Bartl T
Int J Gynecol Cancer; 2024 Jun; 34(6):840-846. PubMed ID: 38508586
[TBL] [Abstract][Full Text] [Related]
15. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
[TBL] [Abstract][Full Text] [Related]
16. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
Palma L; Celli P; Franco C; Cervoni L; Cantore G
J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
[TBL] [Abstract][Full Text] [Related]
18. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
19. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Aizer AA; Abedalthagafi M; Bi WL; Horvath MC; Arvold ND; Al-Mefty O; Lee EQ; Nayak L; Rinne ML; Norden AD; Reardon DA; Wen PY; Ligon KL; Ligon AH; Beroukhim R; Dunn IF; Santagata S; Alexander BM
Neuro Oncol; 2016 Feb; 18(2):269-74. PubMed ID: 26323607
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
